uniQure

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEXINGTON, Mass. and AMSTERDAM, Oct. 03, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

uniQure to Participate in Upcoming Industry Conferences in October

uniQure outlicensed AMT-061, EtranaDez, to CSL Behring who will market the gene therapy for hemophilia B. EtranaDez has a PDUFA date in November and if approved, uniQure will collect a $175 m milestone payment upon commercial launch strengthening their cash position.

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

uniQure to Participate in Upcoming Industry Conferences in September

uniQure N.V. has U.S. and European approvals possible of etranacogene dezaparvovec for treatment of Hemophilia B before end of 2022 and early 2023 respectively. uniQure N.V. has already tapped a partner that is licensed and will help commercialize the drug by the name of CSL Behring.

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

uniQure (QURE) delivered earnings and revenue surprises of 12.50% and 97.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates

~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington's disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant Huntingtin protein (mHTT) observed in cerebral spinal fluid (CSF) ~

uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

This can be attributed to the company reporting positive findings from clinical trials for its Huntington's Disease treatment - AMT-130.

Up 43% In A Month, Will UniQure Stock See Further Gains?

Freeline Therapeutics Holdings

Genespire appoint s Dr. Sabah Sallah as Chief Medical Officer

Genespire appoints Dr. Sabah Sallah as Chief Medical Officer

uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.

uniQure (QURE) Up on Safety Data From Huntington's Disease Study

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

uniQure (QURE) Moves 27% Higher: Will This Strength Last?

UniQure N.V. (NASDAQ: QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease.

UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial

It just reported a packet of promising safety data for its flagship pipeline program.

Why uniQure's Stock Price Jumped Today

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~

uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ: QURE), please note that all the numbers have been updated. The corrected release follows:

CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time. The initial results from the first four patients released in December 2021 disappointed expectations as the company.

Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data

If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

-- If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B -- This milestone underscores CSL Behring's promise to develop and deliver a truly unique portfolio of patient-focused therapies for people with rare and serious medical conditions KING OF PRUSSIA, Pa. , May 24, 2022 /PRNewswire/ -- Global biotherapeutics leader CSL Behring, a business of CSL, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), for priority review, for etranacogene dezaparvovec (also known as CSL222), an investigational gene therapy for the treatment of adults with hemophilia B.

FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review

LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Hybrid Congress 2022 Annual Meeting being held May 16-19 in Washington, D.C.

uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

uniQure (QURE) delivered earnings and revenue surprises of -49.25% and 96.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

~ Partner CSL Behring submitted Marketing Authorization Application (MAA) in Europe for etranacogene dezaparvovec in hemophilia B; MAA validated by the European Medicines Agency (EMA) and granted accelerated assessment ~

uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

uniQure (QURE) Stock Jumps 8.1%: Will It Continue to Soar?

The primary and secondary endpoints for HOPE-B were met when patients with Hemophilia B were treated with etranacogene dezaparvovec.

uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

Marketing Authorization Application (MAA) for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the potential to be the first gene therapy for patients living with hemophilia B MAA filing is supported by the phase 3 HOPE-B study which demonstrated durable and sustained therapeutic effect after a single infusion Milestone underscores CSL Behring's promise to develop and deliver a truly unique portfolio of patient-focused therapies MARBURG, Germany, March 28, 2022 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for etranacogene dezaparvovec (EtranaDez) under its accelerated assessment procedure. Etranacogene dezaparvovec is an investigational adeno-associated virus five (AAV5)-based gene therapy administered as a one-time treatment for hemophilia B patients with a severe bleeding phenotype.

European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B

uniQure (QURE) Moves 5% Higher: Will This Strength Last?

LEXINGTON, Mass. and AMSTERDAM, March 21, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first two cohorts of its randomized, double-blinded, Phase I/II clinical trial of AMT-130 for the treatment of early stage Huntington's disease.

uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease

News for uniQure Stock (QURE)